Established in 2004, Akums Drugs and Pharmaceuticals Limited is a leading pharmaceutical CDMO providing end-to-end solutions in product development, manufacturing, R&D, regulatory dossier preparation, and testing for domestic and international markets. The company manufactures and sells branded drugs and APIs, with a diverse portfolio that includes tablets, capsules, liquids, injectables, eye drops, topicals, and even gummy bears. Akums has commercialized 4,025 formulations across more than 60 dosage forms and served 26 of India’s top 30 pharmaceutical companies by revenue in FY 2023. With 10 manufacturing units offering a combined annual capacity of 49.21 billion units and plans to commission two more by FY 2025, the company continues to scale its operations. Many of its facilities are accredited by global regulatory authorities such as EU-GMP, WHO-GMP, and US NSF. As of September 30, 2023, Akums employed 16,463 personnel, including 7,211 full-time and 9,252 contract staff.